Skip to main content

Day: February 23, 2026

Thirteen Industry Leaders Unite to Define Active Copper Cable Standards

The ACC-MSA aims to accelerate interoperability and innovation for next-generation copper interconnect solutions SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) — Thirteen global leaders in networking, semiconductors and cabling have joined forces to form the Active Copper Cable Multi-Source Agreement (ACC-MSA). This consortium is committed to defining specifications that will enable a robust ecosystem of interoperable ACC solutions, addressing one of the industry’s biggest challenges: reducing power, cost and latency while enhancing the performance of high speed copper interconnect. Co-chaired by MACOM and Semtech, founding members include: AMD, Amphenol, Ciena, Cisco, Dell Technologies, Keysight Technologies, Luxshare Technologies, MACOM Technology Solutions, Molex, Multilane, NVIDIA, Semtech Corporation and TE Connectivity. The...

Continue reading

Compass Diversified Announces Appointment of Eric Weis as President of PrimaLoft; Elevation of Shawn Neville to PrimaLoft Board Chair

WESTPORT, Conn., Feb. 23, 2026 (GLOBE NEWSWIRE) — Compass Diversified (NYSE: CODI) (“CODI”), an owner of leading middle market businesses, today announced the appointment of Eric Weis as President of its subsidiary, PrimaLoft Inc. (“PrimaLoft”). Mr. Weis will succeed Anne Cassava who will step down as CEO of PrimaLoft effective February 23, 2026. In addition, Shawn Neville, Chief Executive Officer of BOA Technology, Inc (“BOA”) and a current member of the Board of Directors of PrimaLoft, has assumed the additional role of Chairman of PrimaLoft. “We thank Anne for her service and many contributions to PrimaLoft, including the development of a stronger product pipeline and organization,” said Zach Sawtelle, Partner and Chief Operating Officer of Compass Group Management. Mr. Weis previously served as Global Chief Commercial and Marketing...

Continue reading

BridgeBio to Participate in March Investor Conferences

PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences:TD Cowen 46th Annual Healthcare Conference, Boston, MA: Fireside Chat on Monday, March 2 at 3:50 pm EST Leerink Partners Global Healthcare Conference, Miami, FL: Fireside Chat on Tuesday, March 10 at 1:00 pm EDT Barclays 28th Annual Global Healthcare Conference, Miami FL: Fireside Chat on Wednesday, March 11 at 12:30 pm EDTTo access the live webcast of BridgeBio’s presentations, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com....

Continue reading

ASP Isotopes Announces Quantum Leap Energy and Necsa Advance Strategic Collaboration Aimed at Production of HALEU Nuclear Fuel

Agreement between QLE’s South African subsidiary and Necsa related to the siting, design, construction, commission and operation of an enrichment facility on the Necsa site in Pelindaba, with QLE’s objective to achieve market readiness for production of nuclear fuel The collaboration leverages QLE’s in-licensed and proprietary enrichment technology and Necsa’s globally-recognized production facilities DALLAS, Feb. 23, 2026 (GLOBE NEWSWIRE) — ASP Isotopes Inc. (NASDAQ: ASPI) (“ASPI”) today announced that on February 20, 2026, a South African subsidiary of Quantum Leap Energy LLC (“QLE” or the “Company”), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, and the South African Nuclear Energy Corporation (“Necsa”) executed...

Continue reading

Verisk Analytics, Inc. Enters into $1.5 Billion Accelerated Share Repurchase Transaction

JERSEY CITY, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) — Verisk Analytics, Inc. (Nasdaq: VRSK) (“Verisk” or the “Company”), a leading strategic data analytics and technology partner to the global insurance industry, today announced that it has entered into accelerated share repurchase agreements (“ASR Agreements”) with each of HSBC Bank USA, National Association and Wells Fargo Bank, National Association (the “ASR Counterparties”) to repurchase an aggregate of $1.5 billion of the Company’s common stock. After giving effect to the ASR Agreements, approximately $1.0 billion will remain available for share repurchases under the Company’s previously announced authorized share repurchase program. The ASR Counterparties are expected to make an aggregate initial delivery of approximately 7.0 million shares of the Company’s common stock to...

Continue reading

South Plains Financial, Inc. Announces Stock Repurchase Program

LUBBOCK, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) — South Plains Financial, Inc. (NASDAQ:SPFI) (“South Plains” or the “Company”), today announced that the board of directors of the Company (the “Board”) approved a new stock repurchase program for up to $10.0 million of the outstanding shares of the Company’s common stock (the “Stock Repurchase Program”). The Stock Repurchase Program will conclude on February 23, 2027, subject to the earlier termination or extension of the Stock Repurchase Program by the Board or the $10.0 million designated for the Stock Repurchase Program are depleted. Under the Stock Repurchase Program, the Company may repurchase shares of the Company’s common stock from time to time through various means, including open market purchases and privately negotiated transactions. Open market repurchases will be conducted...

Continue reading

Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Dr. Axel Paeger, MD, MBA, MBI to its Board of Directors. “We are delighted to welcome Dr. Paeger to our Board of Directors at Anavex,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “Dr. Paeger brings three decades of strong leadership experience in the healthcare industry, offering invaluable guidance as we continue to advance Anavex’s mission of developing...

Continue reading

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com. An audio recording of the conference call will also be available...

Continue reading

Crescent Biopharma to Present at March Investor Conferences

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March:TD Cowen 46th Annual Health Care Conference, fireside chat on Monday, March 2, 2026 at 3:50 p.m. ET in Boston. Leerink Partners 2026 Global Healthcare Conference, fireside chat on Wednesday, March 11, 2026 at 8:40 a.m. ET in Miami.A live webcast of each presentation will be available in the Investors section of Crescent’s website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days. About Crescent Biopharma Crescent Biopharma’s...

Continue reading

Virtuix to Host Third Quarter Fiscal Year 2026 Results Conference Call on Thursday, March 5, 2026 at 8:30 a.m. Eastern Time

AUSTIN, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) — Virtuix Inc. (NASDAQ: VTIX), a leading developer of full-body virtual reality systems, will hold a conference call on Thursday, March 5, 2026 at 8:30 a.m. Eastern time to discuss its results for the third quarter of fiscal year 2026 ended December 31, 2025. Virtuix will also provide updates on joining the Made for Meta program enabling Omni One’s compatibility with Meta Quest headsets and games, recent expansion of Omni One sales to Europe, integration of AI-driven Gaussian splatting technology into its Virtual Terrain Walk (VTW) system, and other initiatives and anticipated milestones. A press release detailing these results will be issued prior to the call. Jan Goetgeluk, Virtuix’s Chief Executive Officer and Chairman, and Thomas McGinnis, Chief Financial Officer, will host the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.